NEW YORK (GenomeWeb) – Pathway Genomics has signed an agreement to make its next-generation sequencing-based clinical genetic tests available in Mexico through health services provider Salud Interactiva, the companies announced today.

Specific terms of the deal were not disclosed.

Pathway sells a variety of NGS assays including ones for diet and weight loss, circulating tumor DNA mutations, hereditary cancer, and carrier screening, as well as metabolic response for commonly prescribed medications.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.

Feb
19
Sponsored by
Pillar Biosciences

This webinar will demonstrate how clinical laboratories can develop their own customized targeted next-generation sequencing (NGS)-based solid tumor panels. 

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Mar
13
Sponsored by
Horizon Discovery

This webinar will discuss development and validation of an assay for detection of microsatellite instability (MSI) based on a novel set of biomarkers.